Quellis is a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases. The company aims to improve the lives of patients by developing antibody therapies. It researches, develops and optimizes monoclonal antibodies. The lead Quellis program targets the discovery of a molecule with high performance and the optimization of discovered monoclonal antibodies. They engineer these monoclonal antibodies to include features intended to deliver greater value and improve patients’ lives.